This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of VVD-130850, a STAT3 Inhibitor, as monotherapy and in combination with immunotherapy in advanced solid and hematologic tumors. LKB1 mutated NSCLC was recruited for combination therapy. The gene discussed is STK11; the disease is non-small cell lung carcinoma.